# OnCo record regeneron (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/regeneron/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "regeneron" ;
  schema:name "Regeneron"@en ;
  schema:description "Regeneron makes Libtayo and has a large portfolio of CD3 bispecifics (odronextamab, linvoseltamab)."@en ;
  schema:url <https://onco.cc/companies/regeneron/>, <https://www.regeneron.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.regeneron.com> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:trials <https://onco.cc/trials/nct06097364/>, <https://onco.cc/trials/nct05730036/>, <https://onco.cc/trials/nct06246916/>, <https://onco.cc/trials/nct05800015/>, <https://onco.cc/trials/nct06149286/>, <https://onco.cc/trials/nct06585410/>, <https://onco.cc/trials/nct06230224/>, <https://onco.cc/trials/nct05608291/>, <https://onco.cc/trials/nct05785767/>, <https://onco.cc/trials/nct06091865/>, <https://onco.cc/trials/nct06091254/>, <https://onco.cc/trials/nct07393282/>, <https://onco.cc/trials/nct06140524/>, <https://onco.cc/trials/nct03972657/>, <https://onco.cc/trials/nct05557591/>, <https://onco.cc/trials/nct06161441/>, <https://onco.cc/trials/nct03916627/>, <https://onco.cc/trials/nct06190951/>, <https://onco.cc/trials/nct07594106/>, <https://onco.cc/trials/nct03888105/>, <https://onco.cc/trials/nct05955508/>, <https://onco.cc/trials/nct06669247/>, <https://onco.cc/trials/nct05828511/>, <https://onco.cc/trials/nct06413680/>, <https://onco.cc/trials/nct06769698/>, <https://onco.cc/trials/nct07455851/>, <https://onco.cc/trials/nct05125016/>, <https://onco.cc/trials/nct04077099/>, <https://onco.cc/trials/nct07154290/>, <https://onco.cc/trials/nct04626635/> .